TRIM6: A Drug Target / Disease Biomarker (G117854)

Target Name: TRIM6

NCBI ID: G117854

TRIM6

TRIM6: A Drug Target / Disease Biomarker

TRIM6, short for Trim6, is a protein that is expressed in the brain and is involved in the regulation of cell growth, differentiation, and survival. It is a key regulator of the microtubules, which are the building blocks of the mitotic spindle that pulls the chromosomes during cell division. In addition to its role in cell division, TRIM6 is also involved in the regulation of the trafficking of proteins to and from the mitochondria, which are the powerhouses of the cell that generate energy.

The discovery of TRIM6 and its function in the regulation of cell growth and differentiation led to its potential as a drug target. Researchers are currently working on developing small molecules that can inhibit the activity of TRIM6 and disrupt its regulation of cell growth and differentiation. These small molecules have the potential to be used to treat a variety of neurological and psychiatric disorders, including cancer, neurodegenerative diseases, and developmental disorders.

In addition to its potential as a drug target, TRIM6 is also a valuable biomarker for the study of neurodegenerative diseases. The progressive loss of TRIM6-positive neurons and the increase in TRIM6-positive neurons that occur in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, make TRIM6 an attractive candidate for the development of diagnostic tests for these disorders.

The study of TRIM6 also has the potential to shed light on the fundamental mechanisms of cell growth and differentiation. By understanding how TRIM6 regulates cell growth and differentiation, researchers may be able to identify new targets for the development of therapeutic agents that can treat a variety of neurological and psychiatric disorders.

In conclusion, TRIM6 is a protein that is expressed in the brain and plays a critical role in the regulation of cell growth, differentiation, and survival. Its potential as a drug target and biomarker make it an attractive target for the development of new therapeutic agents for the treatment of neurological and psychiatric disorders. Further research is needed to fully understand the function of TRIM6 and its potential as a therapeutic agent.

Protein Name: Tripartite Motif Containing 6

Functions: E3 ubiquitin ligase that plays a crucial role in the activation of the IKBKE-dependent branch of the type I interferon signaling pathway (PubMed:24882218, PubMed:31694946). In concert with the ubiquitin-conjugating E2 enzyme UBE2K, synthesizes unanchored 'Lys-48'-linked polyubiquitin chains that promote the oligomerization and autophosphorylation of IKBKE leading to stimulation of an antiviral response (PubMed:24882218). Ubiquitinates also MYC and inhibits its transcription activation activity, maintaining the pluripotency of embryonic stem cells (By similarity). Promotes the association of unanchored 'Lys-48'-polyubiquitin chains with DHX16 leading to enhanced RIGI-mediated innate antiviral immune response (PubMed:35263596)

The "TRIM6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets